ArticleExpert opinion on therapeutic patents2010
Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372.
Article in Expert opinion on therapeutic patents, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Klotho: a novel biomarker for cancer.Journal of cancer research and clinical oncology · 2015Review
- Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism.Annual review of physiology · 2013Review
- FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6.Contributions to nephrology · 2013Article
- The role of Klotho in energy metabolism.Nature reviews. Endocrinology · 2012Review
- Fibroblast growth factor 23: friend or foe in uremia?The Journal of clinical investigation · 2012Article
- Can features of phosphate toxicity appear in normophosphatemia?Journal of bone and mineral metabolism · 2012Review
- The dualistic role of vitamin D in vascular calcifications.Kidney international · 2011Review
- Molecular regulation of phosphate metabolism by fibroblast growth factor-23-klotho system.Advances in chronic kidney disease · 2011Article
- Phosphate toxicity: new insights into an old problem.Clinical science (London, England : 1979) · 2011Review
- Disorders of phosphorus homeostasis.Current opinion in endocrinology, diabetes, and obesity · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The molecular interaction of fibroblast growth factor 23 (FGF23) and klotho is essential for physiologic regulation of phosphate balance. In the absence of klotho, the FGF23 protein cannot exert its physiologic functions, as demonstrated by in vivo mouse genetic studies. Bioactive FGF23 protein loses its phosphate lowering effects in genetically modified mice with no klotho activity. The FGF23-klotho system not only affects phosphate homeostasis but can also influence parathyroid hormone (PTH) and vitamin D activities. Dysregulation of the FGF23-klotho system is noted in a number of human acquired and genetic diseases, including chronic kidney disease. Vitamin D is a strong inducer of both FGF23 and klotho expression, while FGF23 can suppress the renal expression of 1alpha(OH)ase to reduce 1,25(OH)(2)D activity. An understanding of the complex interactions of phosphate, vitamin D and PTH with the FGF23-klotho system has paved the way to explore the therapeutic benefits of modulating the FGF23-klotho system in diseases associated with abnormal mineral ion balance. The patent (WO2009095372) under discussion proposes using fusion polypeptides to manipulate the FGF23-klotho system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.